FDA approves pritelivir for refractory HSV lesions
-
By
-
Teraya Smith
-
October 9, 2026
-
2 min
By
Teraya Smith
October 9, 2026
by E. Meryl Shychuk, Elyse M. C. Harris, Lindsay A. Thompson
May 1, 2026
Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.
June 30, 2026
Investigators linked distinct odor patterns to life stage, sex, and skin microbes, while limited longitudinal evidence leaves their clinical utility uncertain.
October 14, 2026